BENTHAM SCIENCE

CrossMark

Current Medical Imaging

Content list available at: https://benthamscience.com/journals/cmir



REVIEW ARTICLE

The Evolution of Medical Imaging in the Therapeutics of Patients with Skin Cancer

Khushmeen Kaur Brar[1,*], Jeba Shiney O[2], Bhawna Goyal[3] and Ayush Dogra[4]

[1]*Department of ECE, Chandigarh University Mohali, Punjab, India*
[2]*Department of ECE, Alliance University Bangalore, Karnataka 560076, India*
[3]*Department of ECE and UCRD, Chandigarh University Mohali, Punjab, India*
[4]*Chitkara University Institute of Engineering and Technology, Chitkara University, Punjab, India*

Abstract:

Introduction:

Medical imaging mechanization has reformed medical management, empowering doctors to recognize cancer prematurely and promote patient outcomes. Imaging tests are of significant influence in the detection and supervision of cancer patients. Cancer recognition generally necessitates imaging studies that, in most instances, utilize a trivial amount of radiation. Methodologies such as X-rays, computed tomography (CT), magnetic resonance imaging (MRI), and positron emission tomography (PET) are predominant in clinical managerial, incorporating remedy and research.

Background:

Over recent years, diagnostic imaging has progressed from a state of commencement to an advanced level. Numerous modern imaging procedures have evolved. Although contemporary medical imaging comprises image exhibition together with image refining, computer-aided diagnosis (CAD), image inscribing and conserving, and image transference, the majority of which are embraced in picture documentation and communication processes.

Aim:

This review targets to encapsulate toxicology information on skin cancer unpredictability essential to interpretation measures, report important factor that helps in defining skin cancer condition, and possible medical care alternatives or medical attention endorsed referring to diverse aspects involving the size and site of malignancy, the complications, patient's priority and well being. We concisely review various therapy alternatives, methods of radiation autoimmunity, prime observational study designs of medical and distinct radiation resources and cancer risks, and current analysis methodologies and research precision.

Conclusion:

The detail of this paper covers a brief review of research and evolution in medical imaging discipline and mechanism. This review considers the physiology of melanocytes and the pathogenesis of skin cancer using medical imaging. Also, a description of risk factors, prevention methods, screening, various diagnosis methods and different stages of skin cancer, sub-types and different types of treatment methods is provided in this paper for research and development.

Keywords: Medical imaging, Cancer imaging, Optical coherence tomography, Magnetic resonance imaging, Research and development, Research precision.

Article History	Received: September 08, 2023	Revised: November 22, 2023	Accepted: December 12, 2023

1. INTRODUCTION

The human skin comprises 3 layers, specifically Epidermis, Dermis and Hypodermis [1]. The epidermis is a peripheral layer of skin formulated of melanocytes, keratinocytes, Merkel cells and Langerhans cells [2]. It is additionally categorized into 4 layers: the stratum basale, spinosum, granulosum and corneum. The dermis layer consists of narrow, detached papillary dermis and a substantial, compacted reticular dermis [3]. The hypodermis accommodates subcutaneous fat. Any deformity prevailing in the epidermis will bring about several classes of skin complications and skin cancer is one of them. The cancer make

* Address correspondence to this author at the Department of ECE, Chandigarh University Mohali, Punjab, India; E-mail: khushmeenbrar4u@gmail.com



Fig. (1). Types of skin cancer.

an appearance when the active cells mutate and multiply disorderly showing up a lump termed as a tumor. This lump can be mortal which is termed malignant or it is harmless termed as benign. The malignant one has tendency to mutate and expand to internal organs. The other one grows but does not metastasize. The skin cancer, if observed timely can be healed by contemporary drugs, by distinct strategies adopted by dermatologists or by surgery [4]. Since skin cancer can be cured if diagnosed prematurely, the mortality rate is around 1%. But sometimes, it might reach the developed stage and therefore requires medical governance that usually involves a dermatologist, surgeons and radiotherapists. The computer-aided diagnosis or CAD approach is employed for diagnosing the cancer precisely [5]. Nowadays, skin cancer cases are gradually rising, and it has become a global health concern [6]. The skin has 2 principal coatings named epidermis and dermis [7]. The malformation in the epidermis causes different skin complications, the most vulnerable being cancer. The broad classification of skin cancer is Non-melanoma skin cancer (NMSC) and Melanoma skin cancer (MSC) [8, 9], as illustrated in Fig. (**1**).

The NMSC, which is usually harmless, has distinct categories, but the broader classification is Cutaneous Squamous Cell Carcinoma (SCC) and Basal Cell Carcinoma (BCC) [10, 11]. So, the broader classification of Skin cancer includes BCC, SCC, Merkel Cell Carcinoma (MCC) and melanoma [12]. A detailed explanation for all these types is discussed below:

1.1. BCC

As the name suggests, this type of NMSC occurs because of the basal cells that are located in the epidermis. Around 80% of skin cancers originate from these cells. The frequent places where it can originate are the head and neck, but it can originate all over the body. The prime cause of BCC is prolonged subjection to sun and it originates in patients who had gone through radiotherapies earlier. Typically BCC slowly but surely augments and hardly ever expands to the internal organs [13]. Fig. (**2**) depicts a typical BCC image.



Fig. (2). BCC. (https://www.everydayhealth.com/skin-cancer/basal-cell-carcinoma/).



Fig. (3). SCC. (https://www.everydayhealth.com/skin-cancer/what-are-the-different-types-of-skin-cancer/).

1.2. SCC

The uniform, scaly cells in the epidermis are called squamous cells. About 20% of skin cancers originate from these cells and are termed SCC, as shown in Fig. (**3**). It also arises because of prolonged subjection to the sun and can, therefore, be spotted on numerous areas of the skin [14]. It also originates on blistered skin, the portion of skin synthesized or subjected to X-rays. The most frequent places where SCC originates are lips, at spots of a prevailing wound, the skin surrounding the mouth, anus and vagina. The probability of SCC metastasizing to internal organs is 2% - 5%.

1.3. MCC

This is a destructive, invasive and infrequent sort of skin cancer. Also known as neuro endocrine tumor, it begins in the cells that generate hormones under the skin and in the hair follicles [15, 16]. Fig. (**4**) depicts the illustration of MCC.



Fig. (4). MCC.
(https://www.everydayhealth.com/skin-cancer/what-are-the-different-types-of-skin-cancer/).

1.4. Melanoma

It is a life-threatening type of cancer and originates in the melanocytes, which are disintegrated cells whose function is to generate the pigment (melanin) [17]. Melanin provides color to the skin. Fig. (**5**) represents the illustration of melanoma.



Fig. (5). Melanoma.
(PH2 dataset).

BCC and SCC are occasionally systematized and termed keratinocyte carcinoma as they originate in keratinocyte cells.

Skin cancer is categorized into 2 major parts: Non-melanoma [18], and Melanoma [19 - 21]. Melanoma arises because of the deviating reproduction of human cells called melanocytes. Melanocytes are colorant-generating cells raised in the skin, eye, inner ear and leptomeninges. Melanoma stems from the virulent mutation of melanocytes. Whilst melanoma can eventuate in any tissue, the skin is the prevalent location followed by the eye. It initiates when healthy melanocytes transform and spread unmanageably, producing cancerous tumors. It can evolve from a previously present mole that might as well grow on skin where no mole is present. Frequent places where melanoma can grow are the head, neck, the skin under fingernails, genitals, soles of feet or palms of hand [22]. The color can be like that of a mole or cannot have color or be marginally red, termed as amelanotic melanoma [23]. The growth can be deep into the skin which is named as Invasive melanoma [24]. It can penetrate blood vessels and escalate to lymph nodes and other organs of the body, which is given the name Metastatic Melanoma [25]. Melanoma can be further divided into different categories, as mentioned in Fig. (**6**). The 2 major parts are as defined by the pathologists and by the gene mutations. The pathologists subdivided melanoma into 4 parts, namely Superficial Spreading melanoma, Lentigo Maligna, Nodular and Acral Lentiginous [26 - 28], as discussed in Table **1**. The 4 subtypes of melanoma by gene mutations are BRAF, NRAS, NF-1 and KIT [29].

Table 1. Detailed description of melanoma subtypes by pathologists.

Melanoma Type	Occurrence	Site	Description	Growth
Superficial Growth	• Most common • Makes up to 70% of all melanomas	• On the central part of the body, arms and legs • On the back(men) and on the legs (women)	• Develops from existing moles • Often flat and thin with an uneven border • May appear as red, blue, brown, black, grey and white shades	• Grow outwards • Spread across the skin surface • Can grow down the skin
Nodular	• 2nd most common type • Makes about 15%-20% of all melanomas	• Found on areas not exposed to the sun	• Grows and spreads more quickly than other types • Usually black, can be pink or of the same color as our skin	• Grows down in the skin • Growth shaped like a mushroom • Appears as a bump on skin

(Table 1) contd.....

Melanoma Type	Occurrence	Site	Description	Growth
Lentigo Malignant	• Makes up to 10%-15% of all melanomas	• On the face, ears, arms, and skin exposed to the sun	• Tends to get darker as it grows • Usually brown or black	• Grows outward across the surface of the skin before it starts to grow down into the skin
Acral Lentiginous	• Makes up less than 5%of all melanomas	• On palms of hands, soles of feet, under nail bed. • Not related to being exposed to the sun	• Most common in people with dark skin • Appears as a small, flat spot of discolored skin that is dark brown or black • Hard to diagnose	• Grows outward across the surface of the skin before it starts to grow down into the skin



Fig. (6). Subtypes of melanoma as defined by pathologists and by gene mutations.

The details of all the subtypes defined by pathologists are shown in Table **1**.

The subtypes of melanoma defined by gene mutation can be described as:

1.4.1. BRAF Mutations

V-Raf murine sarcoma viral oncogene homolog B1 (BRAF) is a genetic code that ciphers a protein termed B-Raf [30]. This is also referred to as photo-oncogene B-Raf. The protein associated with it is known as serine/threonine-protein kinase B-Raf [31]. This protein works by transmitting signals to cells that are responsible for managing cell maturation. Alterations in BRAF can convert typical cells into carcinogenic ones. The transitions most frequently appear in melanoma. These genes assign directions to a protein accountable for supervising principle cell operations associated with metastasis. It is not necessary that all modifications in B-Raf give rise to cancer. Whenever there is variation in the gene, it ceases to function accurately and addresses cells to partition malignly which gives rise to cancer. Whenever a person has this malignancy, surgeons employ targeted medications to momentarily deactivate the components, provisioning cancer metastasis [32].

1.4.2. NRAS Mutations

Neuroblastoma RAS viral oncogene homolog (NRAS) is a sort of tumor which established in particular nerve tissues [33]. This gene gives directions for producing a protein named N-RAS specifically comprehended in synchronizing cell partitioning. The gene is associated with a category of genes

termed as oncogenes. Once mutated, oncogenes transform naturally into cancerous.

1.4.3. NF-1 Mutations

Neurofibromin 1 gene (NF-1) gene distinguished by variations in skin complexions and expansion of cancers through nerves within the skin, brain and further to internal organs [34].

1.4.4. KIT Mutations

KIT Proto-oncogene is a gene that gives directions for producing a representation of a protein group labeled as receptor tyrosine kinases that mediates impulses *via* plasma membrane towards cell by means of signal transduction [35].

1.5. Melanocytes

Melanoma is basically found in the epidermis and hair follicles. The favored surroundings is the epidermis, but are also present in hair follicles and in the eyes [36]. The function is to create melanin to provide color to hair and eyes. These emerge from immature cells termed as Neural Crest Cells (NCC). The alternative points where melanocytes are present are shown in Fig. (**7**).

1.6. Breslow Thickness

It is a calculation of melanoma depth arising through the skin surface to the deepest part of the cancer. It is calculated in millimeters (mm) and, on this basis, is identified as thin, intermediate and thick [37].

1.6.1. Thin

When the tumor size is below 1mm, it is referred to as thin. Also, there is little chance of metastasis to neighboring lymph nodes and to internal organs of the body.

1.6.2. Intermediate

When the tumor size lies in the range of 1mm and 4mm, it is referred to as the intermediate state.

1.6.3. Thick

When the tumor size exceeds 4 mm, it is termed as thick state. The cancer has extended to internal organs of the body. There is a greater possibility of the tumor reappearing even after surgery.



Fig. (7). Distribution of melanocytes in human tissues.

Table 2. Detailed explanation of TNM staging.

Tumor (T)	Node (N)	Metastasis (M)
Tis: Melanocytes are found only in the outermost layer	N0: Melanocytes are absent in neighboring lymph nodes	M0: Tumor hasn't metastasized to internal organs
T0: Melanocytes are not visible where the tumor originated	-	-

(Table 2) contd.....

Tumor (T)	Node (N)	Metastasis (M)
T1a: Tumor size is below 0.8 mm and is not ulcerated.	N1: Melanocytes present in 1 lymph node	M1: Tumor has metastasized to internal organs
T1b: Tumor size ranges between 0.8mm-1mm, and may or may not be ulcerated.	-	-
T2a: Tumor size ranges between 1mm-2mm and is not ulcerated	N2: Melanocytes present in 2-3 lymph node	-
T2b: Tumor size ranges between 1mm-2mm and is ulcerated	-	-
T3: Tumor size ranges between 2mm-4mm	N3: Melanocytes present in 4 or more lymph node	-
T4a: Tumor size exceeds 4mm and is not ulcerated	-	-
T4b: Tumor size exceeds 4mm and is ulcerated	-	-

In a more elaborated way, TNM staging is considered for determining stages of melanoma that symbolize Tumor, Node and Metastasis (TNM) [38]. It is basically about tumor thickness, transmission to lymph nodes and metastasis to internal organs of the body. The detail is shown in Table **2**.

The other important factor that helps in defining melanoma condition is the mitotic rate. It is calculated as the number of cell partitioning per mm^2. The greater the rate, the higher the possibility of melanoma growth.

1.7. Stages of Melanoma

The first step of melanoma diagnosis is to check if it has spread and to what extent. This procedure is known as staging [39]. The stages are helpful in knowing how much cancer is in the body. There are 4 stages of melanoma, as discussed in Table **3**.

1.8. Elements of Danger

Whatever escalates an individual's possibility of initiating tumor is called a risk factor. A detailed explanation for the same is provided below and illustrated in Fig. (**8**).

1.8.1. Radiant Energy from the Sun

Hours of sunshine are a central problem of originating skin cancer [40]. The population at high metrologies or in regions having intense sunshine throughout the whole year suffers from this malignancy. This is because of the harmful radiations called Ultraviolet (UV) rays [41]. The 2 different types of radiation are UVA and UVB [42, 43]. The UVA radiations are responsible for both melanoma and non-melanoma. This radiation is capable of getting through the glass and perhaps stimulates the aging process and wrinkling of skin, apart from skin cancer [44]. The UVB radiation leads to melanoma and solar dermatitis [45]. But in no way can it pass across a vehicle windshield or any sort of glass.

1.8.2. Getting Domestic Suntan

Practicing tanning beds, parlors, or UV lamps is another factor leading to skin cancer.

1.8.3. Moles

Individuals having abundant moles or anomalous moles under the name of dysplastic nevi *i.e.*, massive moles that are uneven in color and appearance, cause skin cancer.

1.8.4. Light-toned Skin

Melanoma is increasingly frequent in light complexion individuals due to the lower amount of supportive pigment particularly melanin [46].

1.8.5. Hereditary

Anyone with an immediate family detected with melanoma has a 50% higher probability of acquiring the cancer [47].

Table 3. Different stages of melanoma and their description.

Stage	Details of Melanoma Stage	Thickness	Metastasis
0	Restricted only to the epidermis and is known as melanoma *in situ*	Less than 1 mm	Not spread to lymph nodes or to internal organs.
I	Not ulcerated	2mm	Not spread to lymph nodes or to internal organs.
II	May or may not be ulcerated	Exceeds 4 mm	Not spread to lymph nodes or to internal organs.
III A	May or may not be ulcerated	Not exceeding 2 mm	Spread to 1-3 neighboring lymph nodes. Not spread to internal organs.
III B	No symptoms of premature cancer. May or may not be ulcerated	Not exceeding 4mm	Spread to 2-3 neighboring lymph nodes. Spread to nearby portions of skin. Not spread to internal organs.
III C	No symptoms of premature cancer May or may not be ulcerated	4mm or more	Spread to 2 or more neighboring lymph nodes which exact ones could be observed or seen. Spread to nearby portion of skin. Not spread to internal organs.

(Table 3) contd.....

Stage	Details of Melanoma Stage	Thickness	Metastasis
III D	Ulcerated	Exceeding 4mm	Spread to 4 or more lymph nodes or nodes that are clustered. Spread to nearby portions of skin. Not spread to internal organs.
IV	May or may not be ulcerated	Of any thickness	May or may not have spread to lymph nodes Spread to internal organs.



Fig. (8). Risk factors associated with melanoma.

1.8.6. Familiar Melanoma

The transformations in Cyclin-Dependent Kinase Inhibitor 2A (CDKN2A) is yet another reason for skin cancer [48]. The gene typically assists in prohibiting tumors. But a genetic anomaly stimulates it to cease the work the way it must be. This amplifies the vulnerability for a definite class of tumors. Provided that one has a genetic mutation of the CDKN2A gene, he has a disorder titled Familiar Atypical Multiple Mole Melanoma (FAMMM) [49]. This ailment enhances the menace of melanoma. CDKN2A delivers specifications for generating multiple enzymes, typically p16 and p14 proteins. These are cancer restrainers and are associated with suspending cell

partition in former cells. The process is called senescence.

1.9. CDK4

Cyclin Dependent Kinase 4 enciphers a protein notably an element of the serine/threonine kinase genre [50].

1.10. P53

Preserver of gene set that issues directions for producing a protein termed as tumor protein, p53/Tp53 [42, 51, 52]. It governs cell partition by preventing cells from maturing and segregating pretty quickly or in an unregulated manner. It is situated in cell nuclei across the body, where it merges just prior to DNA. If DNA in a cell gets mutilated by destructive additives or UV rays, the protein ascertains if the DNA is going to be restored or the impaired cells will self-sabotage (apoptosis). In case DNA rectifies, p53 drives additional genes to mend the impairment [53]. Provided DNA is incapable of improvement, the protein restrains the cell from splitting and alerts it to undergo apoptosis [54].

1.11. MITF

A gene offers directions for producing a protein termed Melanocytic Inducing Transcription Factor (MITF) [55]. It binds to precise regions of DNA and manages the function of certain genes. That is why it is named as transcription factor. MITF sustains the maturation and role of color inducing cells, melanocytes. It regulates the generation of melanin that assigns color to hair, eyes and skin. Melanocytes are further present in the ear and have significance in listening. MITF controls the evolution of distinctive cells in the retinal colorant somatic cells that nurture the retina (part of the eye that observes luminosity and color).

1.12. Methods for Examining Melanoma

1.12.1. Ultrasound

Utilizing sound propagations to generate a representation of inner parts of the body, comprising an assemblage of lymph glands and soft tissues [56, 57]. This is a non-invasive approach that is versatile and harmless, which might be virtually performed anywhere and can be easily repeated. The mid(7.5-15 MHz) and high frequency (20 MHz) sonographies are prevailing in dermatology for the diagnosis of benign and carcinogenic skin conditions. The primary means of ultrasound comprise the A-mode, B-mode, and Doppler approach [[58]]. The tissue diffusion depth of about 6 mm is attained at a frequency of 20 MHz.

1.12.2. CT Scan

Computed tomography captures images of the viscera utilizing X-rays extracted from distinct angles. With the help of x-rays it takes images of the inside of the body through various angles. The images are then integrated by a computer into a detailed, 3-D image. The picture will exhibit anomalous regions and any tumors.

Sometimes, a particular dye known as a contrast medium is received by the patients prior to the scan. This contrast dye proceeds along the bloodstream during injection in the vein and assists in producing a precise image of certain parts of the body. Besides it might be consumed as a liquid, depending on which organ of the body requires to be examined.

Most frequently scanned regions for cancer incorporate the head, neck, chest, stomach, pelvis, and limbs. Doctors generally utilize full-body CT scans for cancer staging.

The advantages of having a CT scan typically outweigh the hazards. The patients are susceptible to a small amount of radiation at the time of a CT scan. However such a small dosage of radiation has not been demonstrated to induce damage. There might be a slight possibility of a higher risk of cancer for those who require several CT scans and X-rays. In the majority of cases, doctors will utilize minimal-dose CT scans for children or confine the region that needs to be scanned. The images are then put together using a computer into an elaborated 3-D picture that illustrates any deformity or carcinoma. In case melanoma has developed, the scan is utilized in determining the size of the malignancy. A particular colorant known as contrast medium is released prior to the scan to present finer attributes on the picture. It can be vaccinated into a patient's vein or might switch to taking a tablet or a solution to ingest [59].

1.12.3. MRI

Magnetic Resonance Imaging utilizes magnetic fields to create elaborated illustrations. It is exploited for computing the size of the malignancy. This is an imaging test that utilizes high-powered magnets and radio waves to generate detailed, computerized images of the body. A typical MRI machine possesses attenuated excavation space. It is a fine but relatively high-cost mechanism for scheduling treatment for skin cancers. It might as well induce typical MR elements owing to the existence of blood units and melanin in the case of melanoma. MRI might also be utilized for estimating the therapeutic reaction of melanoma and BCC. The cross-sectional MRI of abnormality level in skin cancer is fairly precise and can provide the practitioners with sufficient detail about the category and extent of therapy needed. In addition to providing the diagnostic details, MRI also specifies the result of therapeutic arbitration. A particular colorant known as contrast medium is released prior to the scan into the patient's veins to present finer attributes on the picture [60].

1.12.4. PET-CT Scan

Positron Emission Tomography is typically synthesized to CT-scan. This is also a process of generating images of inner body parts. A limited portion of emissive sugar content is infused inside the patient's body. This is absorbed by the cells that consume the maximum energy. Considering that the cancer has the tendenc

For certain kinds of cancer, this scan is a means to help detect cancer and ascertain the stage of cancer. This stage is a mechanism to illustrate the location of cancer and whether it has metastasized or not. This test also provides information regarding the stage if and by what means the cancer is affecting the functioning of the body. The realization of the cancer stage assists the doctor in determining the best therapy and in estimating the possibility of recovery.y to utilize energy

intensely, it ingests a greater degree of emissive substance. The proportion of this substance is inadequate to be hazardous [61]. This is a kind of test that might be employed in cancer therapy and can be performed together with a CT scan. For this reason, the test is named as a PET-CT scan.

Since a CT scan displays detailed images of the anatomical organs and tissues, a PET scan, on the other hand, can discover unusual activity and is quicker to respond to than distinct imaging tests. This test might also present transformations to the body immediately. The PET-CT scans are employed to provide additional details about the cancer.

Besides knowing the cancer stage, a PET-CT scan can assist the doctors:

• Locate the exact position for an autopsy.

• To determine if the cancer treatment is functioning.

• To examine for new lump or outgrowth when treatment has been done.

• To prepare for radiation therapy.

Prior to the PET-CT scan, the patients are injected with a small dose of a radioactive sugar known as fluorodeoxyglucose-18 (FGD-18). This sugar is absorbed by the cells of the body, and the regions that utilize more energy acquire more of that sugar. Now, cancer cells generally use higher amounts of energy than normal cells. The PET scan exhibits the location of radioactive tracers in the body.

As mentioned earlier, the CT scan takes X-rays of the body through distinct angles. The patients might retrieve a shot of dye prior to the x-rays which assists some of the details to appear finer. At last, a computer integrates the PET and CT pictures to attain a detailed 3-D outcome that reveals something unusual, including cancer.

These scans do transmit a threat of radiation as such kind of scan employs certain radiation out of x-rays, the substance utilized in the PET scan, or both. Examining a restricted part of the body implies slighter radiation.

The advantages of such tests are generally beyond the risks, and at the time of these tests, one will be susceptible to only a little dosage of radiation that has not been exhibited to cause harm.

1.12.5. SLNB and Nuclear Medicine

Sentinel Lymph Node Biopsy is an operative methodology that assists surgeons in discovering if the tumor has metastasized to the lymph nodes [62]. Meanwhile, the tumor expands from where it is initiated to the lymph nodes, and it proceeds along the lymphatic system [63]. SLN is the primary node where the lymphatic system drains. Since melanoma can originate extensively on the skin, the region of SLN is going to be distinct for every patient provided where the malignancy developed. For locating SLN, a colorant and a mild emissive substance are infused practicably close to where the melanoma initiated. It is then followed by SLN, and surgeons detach alternative nodes for examining melanocytes. Later, these are assigned to a medical examiner who examines them and presents a report. As long as melanocytes are absent in SLN, no additional node operation is required. But if melanocytes are present, which is termed as positive SLN, it indicates that the infection has metastasized [64, 65]. The involvement of nuclear medicine in coping with melanoma patients is intensifying. For average thick melanomas, lymphoscintigraphy presents a standard procedure for SLNB. Through the development of single-photon emission CT pictures with integrated CT (SPECT/CT), 3-dimensional anatomic conditions for precise surgical procedures are feasible. In addition to the new insights on the basis of relevant medical data, current research has approved significant technical evolution like SPECT/CT and intra-operative compact imaging tools to explore SN in compound anatomical locales. Nuclear medicine approaches for SNB have exquisitely enhanced the accuracy of melanoma staging. The reliable mechanism for SN localization is compound fluorescent-radioactive tracers together with intra-operative imaging mechanizations, for instance, SPECT and compact gamma cameras. The SNB mechanism depends on the presumption of the gradual metastasis of melanoma *via* the lymphatic system and the SN is enumerated as the intersection on a lymphatic drainage path from the malignancy. Pre-operative lymphoscintigraphy is capable of illustrating all lymph node sites that are at risk for metastases. This technique has been extended to distinct radio-directed implementations and is the foundation of elaborating the Guided intra-operative Scintigraphic Tumor Targeting (GOSTT). This approach was established with the aim of integrating the potentiality of primary and advanced nuclear medicine approaches, which might assist in the intra-operative recognition of attacked tissues with the help of compact gamma cameras or SPECT. For ascertaining the nodes that are suitable to mark SNs, both the regulation of a radioactive tracer and a consecutive pre- or intra-operative mechanism of SN recognition are required. The blue dye methodology, also known as ‘open and see’ for recognizing SNs in suspected regions of lymphatic drainage, was based on the idea of blue-colored lymphatic mediums and lymph nodes precisely draining through the tumor locale instantly after surgical slit. This dye rapidly diffuses over the lymphatic channels, invades into the SNs and does not get trapped. The major disadvantage of such types of dye is that they prevent preoperative lymphatic mapping.

The development of radiotracers in the SLNB technique allowed the determination of the physiologic operation of lymph drainage utilizing gamma cameras. The pictures produced by pre-operative lymphoscintigraphy modified the actual ‘open and see’ criterion to a ‘see and open.’ The ^{99m}Tc-colloids radiotracers are employed for lymphoscintigraphy, which propagate across the lymphatic vessels at a distinct pace relying on the size of the particle and are later confined by macrophages. Premature imaging is suggested because it lets the determination of the radiotracer’s transit across the lymphatic channels and its appearance in the first SN. At the time of attaining the picture, a ^{57}Co or ^{99m}Tc flood source might be utilized to characterize the body shape. At last, the position of every SN is specified on the skin with the help of a pointer and a permanent ink. The latest radiotracer that is established for medical tests is ^{99m}Tc-tilmanocept.

The execution of near-infrared (NIR) dyes allows the intra-operative determination of lymphatic ducts and recognition of

the SN, with the possibility of minimizing surgical time and enhancing the recognition of lymph nodes. The commonly employed radiant agent for SLNB is Indocyanine green.

1.13. Current Scenario

1.13.1. Improved Precaution Methods and Advanced Diagnosis Method

The primary precaution requires safeguarding melanoma from maturing by minimizing sun exposure or the use of artificial tanning procedures. Another approach involves methods of premature recognition of melanoma.

1.13.2. Targeted Therapy

Medical attention that spots on certain genes ascending tumor amplification and endurance [66].

1.13.3. Immunotherapy

Therapeutics equipped to strengthen the body's immune response to combat the malignancy.

1.13.4. ACT, CAR-T and TCR Therapy

Adoptive Cell Therapy, Chimeric Antigen Receptor T-Cell and T-Cell Receptor [67]. ACT is a type of therapy that utilizes the body's defense cells to destroy the tumor. Certain ways include straightaway secluding patient's immune cells and then increasing their count. Alternate methods incorporate hereditary manipulation of the patient's immune cells with the help of gene transfer to boost cancer-fighting proficiency.

1.13.5. TIL Therapy

Tumor Infiltrating Lymphocyte Therapy [68]. The cancer can be in simple words explained as: the immune cells or the killer T cells being specifically dominant over cancer because of their capability to stick to the markers or the foreign substances superficially. A simple explanation is provided in Fig. (**9**).



Fig. (9). Activation of killer T cells.



Fig. (10). Steps involved in TIL therapy.

Just the presence of T cells is not sufficient to assure that they are competent enough to abolish the malignancies. The primary possible obstruction is that T cells should initially be set in motion prior to killing the cancer cells and later have to be efficient in retaining their job for a prolonged time. This is to experience a strong anti-cancer response. Another reason is that the T cells are limited in quantity. TIL therapy is a type of ACT that gathers T cells that have already penetrated the patient's tumors and later initializes and grows. Then, multiple T cells are injected again into the patient's body, where they track down the malignancy and demolish it. A simple explanation is provided in Fig. (**10**).

1.13.6. CAR-T Therapy

In this, the patient's T cells are supplied a fabricated receptor termed a Chimeric Antigen Receptor [69, 70]. The patient's blood is extracted through the vein and is supplied to a machine that separates the T cells. The machine puts additional blood into the body using another tube. Then, T cells are produced by adding CAR, that is later multiplied. These T cells are re-infused into the patient's body. The stepwise explanation is shown in Fig. (**11**).



Fig. (11). Steps involved in CAR T therapy.



Fig. (12). Steps involved in Engineered TCR T therapy.

1.13.7. TCR

The procedure requires removing T cells from the patient's body, and rather than energizing the T cells present, they are supplied with new T cell receptors. This permits the T cells to attack certain cancer antigens [71]. The stepwise explanation is provided in Fig. (**12**).

1.14. NMSC

The skin cancers that are not harmful and generally do not metastasize are NMSC. There are many types of NMSC that are discussed in section IX.

1.14.1. Cause for Alarm and Precautions

The following aspects raise an individual's chance of emerging NMSC.

1.14.2. Solar Vulnerability

The persistent solar vulnerability is the prime cause of originating NMSC. The people residing in rangy regions or sunlit locations have more probability of NMSC occurrence. Also, the people devoting most of their time to sunshine have a higher probability of growing NMSC [72].

1.14.3. Incapacitated Immune System

Individuals having weak immunity because of grafting or because of certain ailments like HIV or AIDS have a greater probability of suffering from NMSC [73, [74, [75].

1.14.4. Commercial Tanning

The use of commercial tanning beds raises the chances of developing NMSC to a greater extent.

1.14.5. Light Complexions

Individuals having lighter skin tones are at greater risk of suffering from NMSC [46].

1.14.6. Actinic Keratoses (AK)

In AK, a crusty blotch of red/brown color is formed on the skin. Over time, it can transform into SCC in some individuals [76].

1.14.7. Sexuality

Usually, men are at higher risk, but research also revealed that senior white men and young women have an elevated probability of NMSC.

1.14.8. Age

The NMSC generally affects people aged 50 years and above. Lately, the analyst discovered that the NMSC in individuals aged 65+ is increasing greatly. However,, adolescents and individuals having aged 20-30 years also get infected.

1.14.9. Sunburns

The NMSC ordinarily affects individuals with burnt or tanned skin, or infected with some ailments. Usually the ultraviolet (UV) radiations happen to be the main ground for NMSC [51].

1.14.10. History of Skin Cancer

Those individuals who earlier had suffered from skin cancer have a greater probability of falling prey to NMSC.

1.14.11. Hereditary

Some infrequent hereditary conditions escalate the probability of getting this disease [77].

1.14.12. Prescriptions

Partakes of prescriptions that overpower the immune system particularly raise the threat of initiating NMSC.

1.14.13. Radiotherapy

The prior radiotherapy-based treatment also raises the probability of getting NMSC.

1.14.14. Human Papillomavirus (HPV) Merkel Cell Polyomavirus (MCV)

These particular viruses are accountable for SCC and MCC respectively [78].

1.14.15. Precautions

There is no validated method for inhibiting NMSC, but the following measures can decrease the threat:

• Staying away from extended sun subjection, avoiding tanning lamps and applying sunscreens.

• Putting on sun-shielding garments.

• Analyzing the skin frequently.

1.15. Types of NMSC

The various types of NMSC are as listed in Fig. (**13**).

1.15.1. Angiosarcoma

This sub-type of NMSC is uncommon and develops in the endothelium and the lymph vessels [79, [80]. These vessels play a role in the body's natural defenses and in assembling and destroying germs and hazardous waste in the body. The occurrence of it is not limited to a specific part of the body and can occur anywhere. But the head and neck are consistently affected and might escalate to breast, liver and heart. The disease also develops in spots subjected to radiotherapy earlier [81].

1.15.1.1. Symptoms

An elevated portion of skin that bears a resemblance to a bruiseor a swelling that becomes wider gradually or inflammation in the region of the affected area. A wound that draws blood while rubbing to relieve itching or if it is knocked on something.

1.15.1.2. Causes

The reason for this NMSC occurrence is not yet apparent. This eventuates by the mutations in a blood vessel lining that bring about modifications in the DNA. The DNA accommodates the specifications instructing the cell to perform a specific activity and directs it to expand abruptly. Also inspires it to stay alive while the normal cells are lost. As a result, the cancer cells gradually accumulate and start expanding to the blood vessels. Also they permeate and tear down normal tissues and ultimately fall to pieces and extend to further body parts. The prior radiotherapy-based treatment also raises the probability of getting this NMSC. The inflammation because of lymph vessel injury or by congestion of lymph fluid (lymphedema) is another reason. Another reason is an infection. Being subjected to certain chemicals like arsenic also raises the chance of it. People congenital to particular gene transformation (neurofibromatosis, maffucci syndrome) have a greater chance of suffering from this disease.

1.15.2. BCC

It initiates in the basal cells, whose capability is to create new cells as former ones abate [82]. The carcinoma emerges as a marginally crystalline outgrowth however, it might take distinct shapes. BCC turns up frequently on those regions of skin which usually remain uncovered and are subjected to the sun like the head and neck [83]. Usually the ultraviolet (UV) radiations happen to be the main ground for BCC. Staying away from extended sun subjection and applying sunscreens might do a favor in safeguarding an individual in resisting BCC. Additionally, it might emerge on those organs that are ordinarily hidden, like the genitals.

1.15.2.1. Symptoms

It emerges like a transformation in the skin like a swelling or bruise that does not show improvement. It appears as a burnished excrescence, which might seem off-white/pink/colorless on fair-skinned individuals. While on darker complexions it appears brown/pitch dark. The small blood vessels are detectable in fair complexions, which are challenging to identifyin darker complexions. This growth possibly bleeds with an incrustation over it. Or an abrasion with darkened dots that are generally brown/black/blue, having moderately elevated and crystalline edges. Or an even scabrous mark having elevated margins that progressively extend enormously. Or a wax-like white abrasion having no specific edge.

1.15.2.2. Causes

BCC arises when a basal cell originates a variation in the DNA. The task of bringing about new skin cells is governed by the DNA. The transformations instruct basal cells to proliferate and to go on building up while normally it ought to die off. Ultimately, the assembling of anomalous cells gives rise to a carcinogenic tumor, *i.e*., an abrasion that pops up on the skin. The mutation to DNA is presumed to be the consequence of UV radiation obtained from the sun as well as from lucrative tanning lamps by persistent solar vulnerability or the abundant hours spent around the sun. To cure distinct skin diseases using radiotherapy elevates the chance of developing this NMSC at former treatment locations. Individuals with fair complexions or light-colored eyes, or grey hair have a greater probability of getting affected. Almost all BCC arises in senior citizens; however, adolescents and individuals aged 20-30 years also get infected. An individual who had BCC at least once has a strong possibility of redeveloping it. Also, the genealogy of skin cancer enhances the threat of initiating BCC. Or partake of prescriptions that overpower the immune system, particularly proliferating the threat of initiating BCC. The virulent metal,

which is present extensively in the surroundings, raises the threat of BCC. The individuals working at places that incorporate the manufacture of arsenic or its utilization or consumption of adulterated water have a strong possibility of getting affected. Some infrequent hereditary conditions escalate the probability of getting this disease. BCC frequently reappears irrespective of successful therapy.

1.15.2.3. Cutaneous B-cell Lymphoma

It is an atypical form of cancer that emerges in white blood cells (WBC) and infects the skin. This disease originates in a specific type of bacterium-destroying WBC termed B-cells [84, 85]. It further has different types, as listed below in Fig. (**14**).



Fig. (13). Classification of different types of NMSC.



Fig. (14). Types of cutaneous B-cell lymphoma.

1.15.3.1. Symptoms

The symptoms comprise a hardened outgrowth below the skin. This growth can have identical color matching the complexions or can be black/purple/pink.

1.15.4. Cutaneous T-cell Lymphoma

It is an atypical form of NMSC that emerges in specific WBCs termed as T-cells and infects the skin. T cells are bacterium-destroying cells, but this NMSC causes them to develop anomalies that play the part of infecting the skin. This NMSC can produce erythema, which is bumped up to some degree or curved squamate blemishes on the skin [86, 87].

1.15.4.1. Symptoms

Curved blotch that is slightly bumped up and might be prickly. Or the marks that are light-toned than adjoining skin. Or the growth that might erupt suddenly. The thickened nodes, losing hair, skin getting thick across palms and feet.

1.15.5. Dermatofibrosarcoma Protuberans

It is an atypical form of NMSC that originates in connective tissue cells in the dermis [88, 89]. It appears as a cyst, or seemingly, its texture might resemble a scratchy mark on the skin. On maturing, the segments of tissues might initiate next to the skin surface. The most frequent places where this malignancy originates are arms, legs and trunk [90].

1.15.6. MCC

This is a destructive, invasive and infrequent sort of skin cancer. Also known as neuroendocrine tumor, it begins in the cells that generate hormones under the skin and in the hair follicles [91].

1.15.6.1. Symptoms

It would appear as a rapidly expanding unproblematic excrescence on the skin. The wound might look red/blue/purple. The MCC can grow at any place on the body, but the most frequent regions are the face, head and neck.

1.15.6.2. Cause

The exact reason for this NMSC is not known. The analysts noticed that a virus termed Merkel Cell Polyomavirus is accountable for it. The virus dwells on the skin but in no way generates any symptoms.

1.15.7. Sebaceous Carcinoma

This is an atypical type of NMSC originating in the oil vesicles. This malignancy ordinarily attacks the eyelids. This growth possibly bleeds with an incrustation over it [92].

1.15.8. SCC

This is a typical NMSC that originates in the squamous cells [93]. It is generally non-dangerous but can be aggressive. If not cured in time, SCC usually extends to internal organs, thereby bringing about severe problems.

1.15.8.1. Symptoms

The most frequent places where SCC originates are lips, head and neck [94, 95, 96]. It can be found at spots of a prevailing wound, the skin surrounding the mouth, anus and vagina. It ordinarily appears as a stiff red protuberance. Or as an even scar having squamate blister. Or as a fresh cut or an elevation on former abrasion. Or a crusty blotch on the lips or inside the mouth. Or a red elevated blotch on the genitals.

1.15.8.2. Causes

This malignancy originates when there are transformations in squamous cell DNA. This is particularly because of hazardous UV radiation. Not only prolonged solar subjection but incapacitated immunity is also accountable.

Table 4. Staging criteria for B-Cell lymphoma.

Tumor (T)	Node (N)	Metastasis (M)
• T1: Sole skin involvement	• N0: No objective lymph node association	• M0: No affirmation of extra glandular nonlymph node disease
• T1(a): Sole abrasion<5cm diameter	• N1: Association of 1 node voiding an area of present or previous skin association	• M1: Extra glandular non lymph node disease present
• T1(b): Sole abrasion>5cm diameter	• N2: Association of 2 or more node voiding an area of present or previous skin association or Association of any node not voiding an area of present or previous skin association	-
• T2: Various abrasions restricted to 1 body part or 2 adjoining body parts.	• N3: Association of central nodes.	-
• T2(a): Infection confined in <15 cm diameter	-	-
• T2(b): Infection confined in >15 cm and <30 cm diameter	-	-
• T2(c): Infection confined in >30 cm diameter	-	-
• T3: Unspecified skin involvement	-	-
• T3(a): Various abrasions restricted to 2 non-adjoining body parts	-	-

Table 5. Staging criteria and symbol meanings for BCC and SCC.

Symbol	Meanings
Tis	Carcinoma *in situ*
T1	Size of tumor < or =2 cm
T2	Size of tumor > 2 cm
T3	Tumor with an invasion of maxilla, mandible and temporal bone
T4	Tumor with invasion of skeleton > 2mm thickness
N0	No metastasis of lymph node
N1	Metastasis in 1 node and < 3 cm in size
N2	Metastasis in 1 node and size ≥ 3 cm or ≤6 cm in size
N3	Metastasis in node and > 6 cm in size
M0	No metastasis
M1	Metastasis

1.16. Stages

It is a method of illustrating the cancer situation and if it has extended over other body parts. Table **4** illustrates the staging criteria for B-cell lymphoma. The TNM terminology is considered, which stands for Tumor, node and metastases.

Staging criteria for BCC and SCC: Table **5** illustrates the staging criteria for BCC and SCC.

1.17. Possible Medical Care Alternatives

Medical attention is endorsed by referring to diverse aspects involving the size and site of malignancy, the complications, patient's priority and well-being [97 - 100]. The below-mentioned options are quite usual for curing NMSC:

1.17.1. Operation

Here, the tumor, along with adjoining tissues is withdrawn in the course of a medical operation. Numerous skin cancers can be withdrawn rapidly in the course of a single abscission. Generally, any further therapy is not required after it. The surgery options include the following:

1.17.1.1. Curettage and Electrodesiccation

Here, the abrasion is withdrawn utilizing a sharp, blockheaded tool termed a curette. The affected surface is later nursed using an electrical phenomenon that assists in restricting immense blood flow and demolishes any leftover cancer cells [101].

1.17.1.2. Moh's Micrographic Surgery

It includes withdrawing the detectable malignancies apart from small shreds about the edges of the surface where it was detected. The fragments are analyzed using a microscope till all of the malignancy is withdrawn [102].

1.17.1.3. Extensive Excision

This procedure is usually employed for withdrawing a massive malignancy. So it incorporates withdrawing tumor along with adjoining robust tissues. Because of this, the gigantic slit is formed to fill up, so a specialist utilizes skin from a distinct section of the body and refills it.

1.17.1.4. Reformed Surgery

This particular procedure is for those who develop NMSC on the face. A specialist in plastic surgery is employed for it.

1.17.2. Radiotherapy

It employs high energy rays for demolishing cancer cells situated at inexecutable locations like close to the eyelids, apex of the nose or the ear. A frequent kind of therapy is external beam therapy. Here, the radiations are imparted to the body employing a machine externally.

1.17.3. Photodynamic Therapy

This is a fusion therapy for AK. Essentially, a healing agent termed aminolevulinic acid is spread on the affected surface. After that, the surface is subjected to a particular light-emitting appliance for a couple of minutes to an hour or more.

1.17.4. Freeze

In this method, liquid nitrogen is utilized (that gets chilled when put on the wound) for freezing and then demolishing atypical cells. The wound later drops off.

1.17.5. Optical Maser

This methodology helps in demolishing cancer cells present in the external skin layer utilizing an intense light beam.

1.17.6. Chemo

This therapy utilizes medications for some weeks to prevent atypical cells from maturing.

1.18. Current Scenario

1.18.1. Epidermal growth factor receptor (EGFR)

This is a neoplasm protein that prompts SCC to mature uncontrollably. The experimentation for evaluating the fusion of radiotherapy and medications attacking EGFR for curing the latter stage of cancer is going on [103].

1.18.2. Hedgehog Pathway Inhibitors (HPI)

These are a category of anti-tumor medication. The analysts are evolving novel HPI for curing latter stage BCC

that is unable to be cured by other methods. Also the, research is going on to determine if the fusion of HPI and diverse methodologies could assist in curing BCC [104].

1.18.3. Comfort Care

The research regarding effective approaches to abbreviating the menace and complications of skin cancer treatment is going on.

1.19. Non-Melanoma Skin Cancer Imaging

For distinct kinds of cancer, a biopsy is the sole reliable approach for the doctor to determine if a certain part of the body has cancer. The following factors are to be taken into consideration while selecting a diagnostic test:

- The kind of cancer speculated
- Various consequences of the disease
- Age and overall health
- The results of previous diagnostic examination

Since NMSC hardly metastasizes, the biopsy is usually the only screening required for identifying and detecting the stage or magnitude of cancer. A biopsy means the elimination of a small proportion of tissue for evaluation under a microscope. At the time of this mechanism, the suspicious skin abrasion is removed generally following a local sedative utilized to anaesthetize the region. In addition to the suspicious skin lesion, a part of the normal tissue surrounding the lesion is also removed which is known as the margin.

The specimen withdrawn amid the biopsy is later examined by a pathologist to ascertain the skin cancer.

It comprises the color, magnitude, and additional details. The specimen is required for other tests on the basis of what the doctor presumes the condition might be prior to the biopsy, known as a suspected diagnosis. Distinct test options like molecular tests determine genes that can be active, transformed, or absent. Distinctive gene or protein examinations might be required to recognize which therapy will work.

Prior to scanning the tissue using a microscope, the examiner or a physician arranges a slide. Through this procedure, the sample is split into thin specimens, referred to as histologic sections. These are later tinted with numerous dyes that reveal the regions of the cells. The next step is to put the sections on a glass slide. Subsequently, a thin envelope known as a cover slip is placed on top to keep the specimen stationary.

The different types of slides prepared are listed as:

1.19.1. Permanent Section

In this case, the examiner puts the sample in a fixative (a medium that holds the sample firm so that in no way does it change) for a couple of hours. The duration for which the sample remains in the fixative relies upon the sample size. The fixative that is most commonly utilized is formalin. It makes the proteins present in the cells turn hard so that they remain unchanged. Later, the examiner puts the fixed sample in a machine that eliminates water from the tissue and substitutes it with paraffin wax. Thereafter, the examiner inserts the sample in a bigger block of paraffin that is resistant and might be preserved indefinitely. As soon as the paraffin block solidifies, a practitioner divides the sample into significantly thin segments with the help of a machine known as a microtome. These thin segments are later floated in water so that they can be gathered onto the slide. The paraffin is diffused from tissue when the segment is on the slide, and water is inserted again. After that a, dyes are utilized to stain components of the cell. The nucleus of the cell incorporates the genes and is tinted dark blue. However the constituents of a cell among the nucleus and the cellular membrane that is cytoplasm is tinted either pink or orange.

1.19.2. Frozen Section

For generating this section, the sample is immediately frozen once the surgeon takes it out of the patient's body. Subsequently, the sample is cut into thin segments with the help of a particular tool known as a cryostat. The segments are put on the slide and tinted utilizing the same procedure employed for a permanent section. Although this procedure is faster however its quality is usually inferior in comparison to the permanent section. This procedure, within a few minutes, states if the tissue is carcinogenic or not and is frequently employed during surgery so as to instantly discover if a patient requires further cancerous tissue removed.

1.19.3. Smear

In this process, if the sample is a liquid or if small units of tissue are in a liquid, a slide is developed in a different way. The sample is smeared on a microscope slide and is allowed to air dry. Later, a fixative is dispersed for fixing it. These fixed cells are later tinted and scanned under a microscope.

No additional therapy other than the biopsy is required if the complete cancer is withdrawn. But in case the cancer cells were noticed in the margins of the withdrawn tissue, further treatment is generally suggested.

Table 6. Comparison of melanoma and NMSC.

Melanoma	NMSC
Emerges in the melanocytic cells	Emerges from keratinocytes.
Most common type: Superficial spreading melanoma (SSM).	Most common type: BCC and SCC
Most common sites: head, neck, trunk in males, lower extremities in females.	Most common sites: Face
Might emerge in a pre-existing mole or as a new spot that changed its size, shape or color.	Emerges as a thick, scaly lump that grows over several weeks to some months.
Treatment options: surgery, radiation, chemotherapy, immunological therapies.	Treatment options: surgery, radiotherapy, cryotherapy, curettage.



Fig. (15). Most common sites and factors responsible for skin cancer.

1.20. Side Effects

Although a lot of therapies are being exploited, but the consequences are also present. The complications are different for different sort of therapies. Frequent problems related to these are severe kidney damage, haemorrhage, abnormal heart rate, contractions, choking, cytokine storm, fluid retention and swelling, paralysis, neutropenic fever, hypogamma globulinemia, asphyxia, immuno suppression, febricity, cardiopulmonary arrest *etc*.

1.21. Comparison

This section provides a contrast between melanoma and NMSC. Table **6** presents a contrast between melanoma and NMSC.

2. MOST COMMON SITES

Fig. (**15**) depicts the typical areas and elements accountable for skin cancer in a specific area.

CONCLUSION

Imaging can have an extensive contribution to the progression and accomplishment of forbearing treatment in cancer. The realization of this objective entails contemporary strategies that extend and eventually substitute the current intuitive qualitative estimation of tumor attributions. In this paper, skin cancer biology is described. It provides essential details about skin cancer and the organs of the body it may attack. The paper illustrates the modifications and medical issues NMSC and MSC can generate. It represents the causes that may enhance the possibility of expanding skin cancer and methods to help minimize the menace. It also provides details about various tests required to know more about the reasons for the symptoms. A detailed explanation of the methodology used to observe the stage and the stage groups for skin cancer. A detailed explanation of various treatment types that doctors utilize for treating patients with skin cancer is provided, and the latest research that is being carried out to understand more about skin cancer is explained in this paper. To minimize future estimated skin cancers from symptomatic operations, we reported the general utilization of medical imaging relevance benchmark for conclusions.

LIST OF ABBREVIATIONS

CT	=	Computed Tomography
MRI	=	Magnetic Resonance Imaging
PET	=	Positron Emission Tomography
CAD	=	Computer-aided Diagnosis

CONSENT FOR PUBLICATION

Not applicable.

FUNDING

None.

CONFLICT OF INTEREST

Dr. Ayush Dogra is the Executive Guest Editor of the journal Current Medical Imaging.

ACKNOWLEDGEMENTS

Declared none.

REFERENCES

[1] Losquadro WD. Anatomy of the skin and the pathogenesis of nonmelanoma skin cancer. Facial Plast Surg Clin North Am 2017; 25(3): 283-9. [http://dx.doi.org/10.1016/j.fsc.2017.03.001] [PMID: 28676156]

[2] Dhinagar NJ, Celenk M. Analysis of regularity in skin pigmentation and vascularity by an optimized feature space for early cancer classification. 2014 7th International Conference on Biomedical Engineering and Informatics. 14-16 October 2014; Dalian, China. 2014. [http://dx.doi.org/10.1109/BMEI.2014.7002865]

[3] McGrath JA, Uitto J. Anatomy and Organization of Human Skin. 8th ed. Rook's Textbook Dermatology 2010; 1: pp. 34-86. [http://dx.doi.org/10.1002/9781444317633.ch3]

[4] Silpa SR, v C. A review on skin cancer. Int Res J Pharm 2013; 4(8): 83-8. [http://dx.doi.org/10.7897/2230-8407.04814]

[5] Kaushal C, Bhat S, Koundal D, Singla A. Recent trends in computer assisted diagnosis (CAD) system for breast cancer diagnosis using histopathological images. IRBM 2019; 40(4): 211-27. [http://dx.doi.org/10.1016/j.irbm.2019.06.001]

[6] Urban K, Mehrmal S, Uppal P, Giesey RL, Delost GR. The global burden of skin cancer: A longitudinal analysis from the Global Burden of Disease Study, 1990–2017. JAAD International 2021; 2: 98-108. [http://dx.doi.org/10.1016/j.jdin.2020.10.013] [PMID: 34409358]

[7] Bergfelt DR. Anatomy and physiology of the skin. In: Equine Breeding Management and Artificial Insemination. 2009; pp. 113-31. [http://dx.doi.org/10.1016/B978-1-4160-5234-0.00011-8]

[8] Griffin LL, Ali FR, Lear JT, Lear JT. Non-melanoma skin cancer. Clin Med 2016; 16(1): 62-5. [http://dx.doi.org/10.7861/clinmedicine.16-1-62] [PMID: 26833519]

[9] Das PK, Jadon S, Pradhan S, Kar DM. A review article on melanoma. J Pharm Sci Res 2016; 8(2): 112-7.

[10] Dika E, Scarfì F, Ferracin M, *et al.* Basal cell carcinoma: A comprehensive review. Int J Mol Sci 2020; 21(15): 5572. [http://dx.doi.org/10.3390/ijms21155572] [PMID: 32759706]

[11] Shulstad RM, Proper S. Squamous cell carcinoma A review of etiology, pathogenesis, treatment, and variants. J Dermatol Nurses Assoc 2019; 2(10): 1-5.

[12] Walsh NM, Cerroni L. Merkel cell carcinoma: A review. J Cutan Pathol 2021; 48(3): 411-21. [http://dx.doi.org/10.1111/cup.13910] [PMID: 33128463]

[13] Naik PP, Desai MB. Basal cell carcinoma: A narrative review on contemporary diagnosis and management. Oncol Ther 2022; 10(2): 317-35. [http://dx.doi.org/10.1007/s40487-022-00201-8] [PMID: 35729457]

[14] Kabir S, Schmults CD, Ruiz ES. A review of cutaneous squamous cell carcinoma epidemiology, diagnosis, and management. Int J Cancer Manag 2018; 11(1): 1-9. [http://dx.doi.org/10.5812/ijcm.60846]

[15] Ambwani RKS, Misra AK. Merkel cells: A collective review of current concepts. Int J Appl Basic Med Res 2017; 2019(11): 193-5. [http://dx.doi.org/10.4103/ijabmr.IJABMR]

[16] Harms PW, Harms KL, Moore PS, *et al.* The biology and treatment of Merkel cell carcinoma: Current understanding and research priorities. Nat Rev Clin Oncol 2018; 15(12): 763-76. [http://dx.doi.org/10.1038/s41571-018-0103-2] [PMID: 30287935]

[17] Yamaguchi Y, Hearing VJ. Melanocytes and their diseases. Cold Spring Harb Perspect Med 2014; 4(5): a017046. [http://dx.doi.org/10.1101/cshperspect.a017046] [PMID: 24789876]

[18] Didona D, Paolino G, Bottoni U, Cantisani C. Non melanoma skin cancer pathogenesis overview. Biomedicines 2018; 6(1): 6. [http://dx.doi.org/10.3390/biomedicines6010006] [PMID: 29301290]

[19] Singh N, Kaur P. Comprehensive review of techniques used to detect skin lesion. 2017 2nd International Conference for Convergence in Technology (I2CT). 07-09 April 2017; Mumbai, India. 2017. [http://dx.doi.org/10.1109/I2CT.2017.8226102]

[20] Davids LM, Kleem B. The menace of melanoma: A photodynamic approach to adjunctive cancer therapy. In: Melanoma - From Early Detection to Treatment. IntechOpen 2013. [http://dx.doi.org/10.5772/53676]

[21] Nie D. Classification of melanoma and clark nevus skin lesions based on Medical Image Processing Techniques. 2011 3rd International Conference on Computer Research and Development. 11-13 March 2011; Shanghai, China. 2011.

[22] Apalla Z, Lallas A, Sotiriou E, Lazaridou E, Ioannides D. Epidemiological trends in skin cancer. Dermatol Pract Concept 2017; 7(2): 1-6. [http://dx.doi.org/10.5826/dpc.0702a01] [PMID: 28515985]

[23] Gong HZ, Zheng HY, Li J. Amelanotic melanoma. Melanoma Res 2019; 29(3): 221-30. [http://dx.doi.org/10.1097/CMR.0000000000000571] [PMID: 30672881]

[24] McPherson M, Elwood M, English DR, Baade PD, Youl PH, Aitken JF. Presentation and detection of invasive melanoma in a high-risk population. J Am Acad Dermatol 2006; 54(5): 783-92. [http://dx.doi.org/10.1016/j.jaad.2005.08.065] [PMID: 16635658]

[25] Maverakis E, Cornelius L, Bowen G, *et al.* Metastatic melanoma - a review of current and future treatment options. Acta Derm Venereol 2015; 95(5): 516-24. [http://dx.doi.org/10.2340/00015555-2035] [PMID: 25520039]

[26] Lang J, MacKie RM. Prevalence of exon 15 BRAF mutations in primary melanoma of the superficial spreading, nodular, acral, and lentigo maligna subtypes. J Invest Dermatol 2005; 125(3): 575-9. [http://dx.doi.org/10.1111/j.0022-202X.2005.23833.x] [PMID: 16117801]

[27] Iii WPC, Reed RJ, Krementz ET. Acral lentiginous melanoma. Arch Dermatol 2015.

[28] Daniel Su WP. Malignant melanoma: Basic approach to clinicopathologic correlation. Mayo Clin Proc 1997; 72(3): 267-72. [http://dx.doi.org/10.4065/72.3.267] [PMID: 9070204]

[29] Mar VJ, Wong SQ, Li J, *et al.* BRAF/NRAS wild-type melanomas have a high mutation load correlating with histologic and molecular signatures of UV damage. Clin Cancer Res 2013; 19(17): 4589-98. [http://dx.doi.org/10.1158/1078-0432.CCR-13-0398] [PMID: 23833303]

[30] Lugović-Mihić L, Ćesić D, Vuković P, Novak Bilić G, Šitum M, Špoljar S. Melanoma development: Current knowledge on melanoma pathogenesis. Acta Dermatovenerol Croat 2019; 27(3): 163-8. [PMID: 31542060]

[31] Michaloglou C, Vredeveld LCW, Soengas MS, *et al.* BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature 2005; 436(7051): 720-4. [http://dx.doi.org/10.1038/nature03890] [PMID: 16079850]

[32] Davies H, Bignell GR, Cox C, *et al.* Mutations of the BRAF gene in human cancer. Nature 2002; 417(6892): 949-54. [http://dx.doi.org/10.1038/nature00766] [PMID: 12068308]

[33] Martins da Silva V, Martinez-Barrios E, Tell-Martí G, *et al.* Genetic abnormalities in large to giant congenital nevi: Beyond nras mutations. J Invest Dermatol 2019; 139(4): 900-8. [http://dx.doi.org/10.1016/j.jid.2018.07.045] [PMID: 30359577]

[34] Coricovac D, Dehelean C, Moaca EA, *et al.* Cutaneous melanoma—a long road from experimental models to clinical outcome: A review. Int J Mol Sci 2018; 19(6): 1566. [http://dx.doi.org/10.3390/ijms19061566] [PMID: 29795011]

[35] Delyon J, Lebbe C, Dumaz N. Targeted therapies in melanoma beyond

BRAF: Targeting NRAS-mutated and KIT-mutated melanoma. Curr Opin Oncol 2020; 32(2): 79-84.
[http://dx.doi.org/10.1097/CCO.0000000000000606] [PMID: 31833955]

[36] Tolleson WH. Human melanocyte biology, toxicology, and pathology. J Environ Sci Health Part C Environ Carcinog Ecotoxicol Rev 2005; 23(2): 105-61.
[http://dx.doi.org/10.1080/10590500500234970] [PMID: 16291526]

[37] Marghoob AA, Koenig K, Bittencourt FV, Kopf AW, Bart RS. Breslow thickness and Clark level in melanoma. Cancer 2000; 88(3): 589-95.
[http://dx.doi.org/10.1002/(SICI)1097-0142(20000201)88:3<589::AID-CNCR15>3.0.CO;2-I] [PMID: 10649252]

[38] Petro A, Schwartz J, Johnson T. Current melanoma staging. Clin Dermatol 2004; 22(3): 223-7.
[http://dx.doi.org/10.1016/j.clindermatol.2003.12.010] [PMID: 15262308]

[39] Le MN, Lee E, Singh B. The evolution of staging of cutaneous squamous cell carcinomas: A structured review. Int J Head Neck Surg 2017; 8(2): 57-63.
[http://dx.doi.org/10.5005/jp-journals-10001-1307]

[40] Wu S, Cho E, Li WQ, Weinstock MA, Han J, Qureshi AA. History of severe sunburn and risk of skin cancer among women and men in 2 prospective cohort studies. Am J Epidemiol 2016; 183(9): 824-33.
[http://dx.doi.org/10.1093/aje/kwv282] [PMID: 27045074]

[41] Downs NJ, Axelsen T, Schouten P, Igoe DP, Parisi AV, Vanos J. Biologically effective solar ultraviolet exposures and the potential skin cancer risk for individual gold medalists of the 2020 Tokyo Summer Olympic Games. Temperature 2020; 7(1): 89-108.
[http://dx.doi.org/10.1080/23328940.2019.1581427] [PMID: 32166106]

[42] Ouhtit A, Konrad Muller H, Gorny A, Ananthaswamy HN. UVB-induced experimental carcinogenesis: Dysregulation of apoptosis and p53 signalling pathway. Redox Rep 2000; 5(2-3): 128-9.
[http://dx.doi.org/10.1179/135100000101535447] [PMID: 10939292]

[43] Moan J, Grigalavicius M, Baturaite Z, Dahlback A, Juzeniene A. The relationship between UV exposure and incidence of skin cancer. Photodermatol Photoimmunol Photomed 2015; 31(1): 26-35.
[http://dx.doi.org/10.1111/phpp.12139] [PMID: 25213656]

[44] Parrado C, Mercado-Saenz S, Perez-Davo A, Gilaberte Y, Gonzalez S, Juarranz A. Environmental stressors on skin aging. Mechanistic insights. Front Pharmacol 2019; 10(July): 759.
[http://dx.doi.org/10.3389/fphar.2019.00759] [PMID: 31354480]

[45] Hart PH, Norval M. Ultraviolet radiation-induced immunosuppression and its relevance for skin carcinogenesis. Photochem Photobiol Sci 2018; 17(12): 1872-84.
[http://dx.doi.org/10.1039/c7pp00312a] [PMID: 29136080]

[46] Mitra D, Luo X, Morgan A, *et al.* An ultraviolet-radiation-independent pathway to melanoma carcinogenesis in the red hair/fair skin background. Nature 2012; 491(7424): 449-53.
[http://dx.doi.org/10.1038/nature11624] [PMID: 23123854]

[47] Leachman SA, Lucero OM, Sampson JE, *et al.* Identification, genetic testing, and management of hereditary melanoma. Cancer Metastasis Rev 2017; 36(1): 77-90.
[http://dx.doi.org/10.1007/s10555-017-9661-5] [PMID: 28283772]

[48] Pópulo H, Soares P, Lopes JM. Insights into melanoma: Targeting the mTOR pathway for therapeutics. Expert Opin Ther Targets 2012; 16(7): 689-705.
[http://dx.doi.org/10.1517/14728222.2012.691472] [PMID: 22620498]

[49] Fusaro RM, Lynch HT, Kimberling WJ. Familial atypical multiple mole melanoma syndrome (FAMMM). Arch Dermatol 1983; 119(1): 2-3.
[http://dx.doi.org/10.1001/archderm.1983.01650250006002] [PMID: 6849558]

[50] Smalley KSM, Contractor R, Nguyen TK, *et al.* Identification of a novel subgroup of melanomas with KIT/cyclin-dependent kinase-4 overexpression. Cancer Res 2008; 68(14): 5743-52.
[http://dx.doi.org/10.1158/0008-5472.CAN-08-0235] [PMID: 18632627]

[51] Brash DE, Rudolph JA, Simon JA, *et al.* A role for sunlight in skin cancer: UV-induced p53 mutations in squamous cell carcinoma. Proc Natl Acad Sci 1991; 88(22): 10124-8.
[http://dx.doi.org/10.1073/pnas.88.22.10124] [PMID: 1946433]

[52] Nelson MA, Einspahr JG, Alberts DS, *et al.* Analysis of the p53 gene in human precancerous actinic keratosis lesions and squamous cell cancers. Cancer Lett 1994; 85(1): 23-9.
[http://dx.doi.org/10.1016/0304-3835(94)90234-8] [PMID: 7923098]

[53] Ziegler A, Jonason AS, Leffellt DJ, *et al.* Sunburn and p53 in the onset of skin cancer. Nature 1994; 372(6508): 773-6.
[http://dx.doi.org/10.1038/372773a0] [PMID: 7997263]

[54] Cui R, Widlund HR, Feige E, *et al.* Central role of p53 in the suntan response and pathologic hyperpigmentation. Cell 2007; 128(5): 853-64.
[http://dx.doi.org/10.1016/j.cell.2006.12.045] [PMID: 17350573]

[55] Gray-Schopfer V, Wellbrock C, Marais R. Melanoma biology and new targeted therapy. Nature 2007; 445(7130): 851-7.
[http://dx.doi.org/10.1038/nature05661] [PMID: 17314971]

[56] Mason TJ, Riera E, Vercet A, Lopez-Buesa P. Application of ultrasound. In: Emerging Technologies for Food Processing. Academic Press 2005; pp. 323-51.
[http://dx.doi.org/10.1016/B978-012676757-5/50015-3]

[57] Koundal D, Gupta S, Singh S. Computer aided thyroid nodule detection system using medical ultrasound images. Biomed Signal Process Control 2018; 40: 117-30.
[http://dx.doi.org/10.1016/j.bspc.2017.08.025]

[58] Dill-Müller D, Maschke J. Ultraschalldiagnostik in der dermatologie. JDDG - J Ger Soc Dermatology 2007; 5(8): 689-707.
[http://dx.doi.org/10.1111/j.1610-0387.2007.06453.x] [PMID: 17659044]

[59] Mohr P, Eggermont AMM, Hauschild A, Buzaid A. Staging of cutaneous melanoma. Ann Oncol 2009; 20(S4): vi14-21.
[http://dx.doi.org/10.1093/annonc/mdp256]

[60] Dinnes J, Ferrante di Ruffano L, Takwoingi Y, *et al.* Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma. Cochrane Libr 2019; 2019(7): CD012806.
[http://dx.doi.org/10.1002/14651858.CD012806.pub2] [PMID: 31260100]

[61] Buchbender C, Heusner TA, Lauenstein TC, Bockisch A, Antoch G. Oncologic PET/MRI, part 2: Bone tumors, soft-tissue tumors, melanoma, and lymphoma. J Nucl Med 2012; 53(8): 1244-52.
[http://dx.doi.org/10.2967/jnumed.112.109306] [PMID: 22782313]

[62] Leong SPL, Mihm MC Jr, Murphy GF, *et al.* Progression of cutaneous melanoma: Implications for treatment. Clin Exp Metastasis 2012; 29(7): 775-96.
[http://dx.doi.org/10.1007/s10585-012-9521-1] [PMID: 22892755]

[63] Brănişteanu DE, Cozmin M, Porumb-Andrese E, *et al.* Sentinel lymph node biopsy in cutaneous melanoma, a clinical point of view. Medicina 2022; 58(11): 1589.
[http://dx.doi.org/10.3390/medicina58111589] [PMID: 36363546]

[64] Miller JR III, Lo SN, Nosrati M, *et al.* Improving selection for sentinel lymph node biopsy among patients with melanoma. JAMA Netw Open 2023; 6(4): e236356.
[http://dx.doi.org/10.1001/jamanetworkopen.2023.6356] [PMID: 37074717]

[65] Salguero-Fernández I, Rios-Buceta L, Jaén-Olasolo P. [Sentinel lymph node in nonmelanoma skin cancer]. Actas Dermo-Sifiliográficas 2011; 102(8): 589-98.
[http://dx.doi.org/10.1016/j.adengl.2011.05.001] [PMID: 21907945]

[66] Olszanski AJ. Current and future roles of targeted therapy and immunotherapy in advanced melanoma. J Manag Care Pharm 2014; 20(4): 346-56.
[http://dx.doi.org/10.18553/jmcp.2014.20.4.346] [PMID: 24684639]

[67] Junttila MR, de Sauvage FJ. Influence of tumour micro-environment heterogeneity on therapeutic response. Nature 2013; 501(7467): 346-54.
[http://dx.doi.org/10.1038/nature12626] [PMID: 24048067]

[68] Kelderman S, Heemskerk B, Fanchi L, *et al.* Antigen□specific TIL therapy for melanoma: A flexible platform for personalized cancer immunotherapy. Eur J Immunol 2016; 46(6): 1351-60.
[http://dx.doi.org/10.1002/eji.201545849] [PMID: 27005018]

[69] Simon B, Uslu U. CAR □T cell therapy in melanoma: A future success story? Exp Dermatol 2018; 27(12): 1315-21.
[http://dx.doi.org/10.1111/exd.13792] [PMID: 30288790]

[70] Feldman L, Brown C, Badie B. Chimeric antigen receptor (CAR) T cell therapy for glioblastoma. Neuromolecular Med 2022; 24(1): 35-40.
[http://dx.doi.org/10.1007/s12017-021-08689-5] [PMID: 34665390]

[71] Coccoris M, Straetemans T, Govers C, Lamers C, Sleijfer S, Debets R. T cell receptor (TCR) gene therapy to treat melanoma: Lessons from clinical and preclinical studies. Expert Opin Biol Ther 2010; 10(4): 547-62.
[http://dx.doi.org/10.1517/14712591003614756] [PMID: 20146634]

[72] Schmitt J, Haufe E, Trautmann F, *et al.* Is ultraviolet exposure acquired at work the most important risk factor for cutaneous

squamous cell carcinoma? Results of the population-based case-control study FB-181. Br J Dermatol 2018; 178(2): 462-72. [http://dx.doi.org/10.1111/bjd.15906] [PMID: 28845516]

[73] Collins L, Quinn A, Stasko T. Skin cancer and immunosuppression. Dermatol Clin 2019; 37(1): 83-94. [http://dx.doi.org/10.1016/j.det.2018.07.009] [PMID: 30466691]

[74] Yeung H, Balakrishnan V, Luk KMH, Chen SC. Risk of skin cancers in older persons living with HIV. J Assoc Nurses AIDS Care 2019; 30(1): 80-6. [http://dx.doi.org/10.1097/JNC.0000000000000001] [PMID: 30586085]

[75] Chang AY, Doiron P, Maurer T. Cutaneous malignancies in HIV. Curr Opin HIV AIDS 2017; 12(1): 57-62. [http://dx.doi.org/10.1097/COH.0000000000000338] [PMID: 27875372]

[76] Sinclair R, Baker C, Spelman L, Supranowicz M, MacMahon B. A review of actinic keratosis, skin field cancerisation and the efficacy of topical therapies. Australas J Dermatol 2021; 62(2): 119-23. [http://dx.doi.org/10.1111/ajd.13447] [PMID: 32840870]

[77] Bonilla X, Parmentier L, King B, *et al.* Genomic analysis identifies new drivers and progression pathways in skin basal cell carcinoma. Nat Genet 2016; 48(4): 398-406. [http://dx.doi.org/10.1038/ng.3525] [PMID: 26950094]

[78] Nichols AJ, Gonzalez A, Clark ES, *et al.* Combined systemic and intratumoral administration of human papillomavirus vaccine to treat multiple cutaneous basaloid squamous cell carcinomas. JAMA Dermatol 2018; 154(8): 927-30. [http://dx.doi.org/10.1001/jamadermatol.2018.1748] [PMID: 29971321]

[79] Ishida Y, Otsuka A, Kabashima K. Cutaneous angiosarcoma: Update on biology and latest treatment. Curr Opin Oncol 2018; 30(2): 107-12. [http://dx.doi.org/10.1097/CCO.0000000000000427] [PMID: 29194075]

[80] Goerdt LV, Schneider SW, Booken N. Cutaneous angiosarcomas: Molecular pathogenesis guides novel therapeutic approaches. J Dtsch Dermatol Ges 2022; 20(4): 429-43. [http://dx.doi.org/10.1111/ddg.14694] [PMID: 35218306]

[81] Cao J, Wang J, He C, Fang M. Angiosarcoma: A review of diagnosis and current treatment. Am J Cancer Res 2019; 9(11): 2303-13.

[82] Dubai P, Bhatt S, Joglekar C, Patii S. Skin cancer detection and classification 2017 6th International Conference on Electrical Engineering and Informatics (ICEEI). 25-27 November 2017; Langkawi, Malaysia. 2017; pp. 1-6. [http://dx.doi.org/10.1109/ICEEI.2017.8312419]

[83] Janjua OS, Qureshi SM. Basal cell carcinoma of the head and neck region: an analysis of 171 cases. J Skin Cancer 2012; 2012: 1-4. [http://dx.doi.org/10.1155/2012/943472] [PMID: 23316370]

[84] Vitiello P, Sica A, Ronchi A, Caccavale S, Franco R, Argenziano G. Primary cutaneous b-cell lymphomas: An update. Front Oncol 2020; 10(May): 651. [http://dx.doi.org/10.3389/fonc.2020.00651] [PMID: 32528871]

[85] Lucioni M, Fraticelli S, Neri G, *et al.* Primary cutaneous b-cell lymphoma: An update on pathologic and molecular features. Hemato 2022; 3(2): 318-40. [http://dx.doi.org/10.3390/hemato3020023]

[86] Malpica L. Paving the path to better understanding T-cell lymphomas: The importance of lymphoma registries. Lancet Reg Health West Pac 2021; 10: 100134. [http://dx.doi.org/10.1016/j.lanwpc.2021.100134] [PMID: 34327347]

[87] Bagherani N, Smoller BR. An overview of cutaneous T cell lymphomas. F1000 Res 2016; 5(0): 1882. [http://dx.doi.org/10.12688/f1000research.8829.1] [PMID: 27540476]

[88] Osime C, Irowa O, Obaseki D, Osaigbovo E. Dermatofibrosarcoma protuberans of the breast in a male: A case report and review of the literature. AJMHS 2014; 13(2): 119. [http://dx.doi.org/10.4103/2384-5589.144583]

[89] Sheidaei S, Salehi M, Abedian kenari F, Jafari HR. Dermatofibrosarcoma protuberans challenges: A case series and review of the literature. J Med Case Reports 2023; 17(1): 18. [http://dx.doi.org/10.1186/s13256-022-03728-6] [PMID: 36653860]

[90] Hao X, Billings SD, Wu F, *et al.* Dermatofibrosarcoma protuberans: Update on the diagnosis and treatment. J Clin Med 2020; 9(6): 1752. [http://dx.doi.org/10.3390/jcm9061752] [PMID: 32516921]

[91] Schmerling RA, Casas JG, Cinat G, *et al.* Burden of disease, early diagnosis, and treatment of Merkel cell carcinoma in Latin America. J Glob Oncol 2018; 4(4): 1-11. [http://dx.doi.org/10.1200/JGO.18.00041] [PMID: 30085832]

[92] Michael RS, Gabriel JS, Eric AE, Elizabeth KC, Alisa MG. Sebaceous carcinoma epidemiology and genetics: Emerging concepts and clinical implications for screening, prevention, and treatment. Clin Cancer Res 2021; 27(2): 389-93.

[93] Green AC, Olsen CM. Cutaneous squamous cell carcinoma: An epidemiological review. Br J Dermatol 2017; 177(2): 373-81. [http://dx.doi.org/10.1111/bjd.15324] [PMID: 28211039]

[94] Kang SY, Toland AE. High risk cutaneous squamous cell carcinoma of the head and neck. World J Otorhinolaryngol Head Neck Surg 2016; 2(2): 136-40. [http://dx.doi.org/10.1016/j.wjorl.2016.05.004] [PMID: 29204558]

[95] Lubov J, Labbé M, Sioufi K, *et al.* Prognostic factors of head and neck cutaneous squamous cell carcinoma: A systematic review. J Otolaryngol Head Neck Surg 2021; 50(1): 54. [http://dx.doi.org/10.1186/s40463-021-00529-7] [PMID: 34493343]

[96] Johnson DE, Burtness B, Leemans CR, Lui VWY, Bauman JE, Grandis JR. Head and neck squamous cell carcinoma. Nat Rev Dis Primers 2020; 6(1): 92. [http://dx.doi.org/10.1038/s41572-020-00224-3] [PMID: 33243986]

[97] Shimizu I, Cruz A, Chang KH, Dufresne RG. Treatment of squamous cell carcinoma *in situ*: A review. Dermatol Surg 2011; 37(10): 1394-411. [http://dx.doi.org/10.1111/j.1524-4725.2011.02088.x] [PMID: 21767324]

[98] Shende P, Vaidya J, Gaud RS. Pharmacotherapeutic approaches for transportation of anticancer agents *via* skin. Artif Cells Nanomed Biotechnol 2018; 46(S3): S423-33. [http://dx.doi.org/10.1080/21691401.2018.1498349]

[99] Potenza C, Bernardini N, Balduzzi V, *et al.* A review of the literature of surgical and nonsurgical treatments of invasive squamous cells carcinoma. BioMed Res Int 2018; 2018: 1-9. [http://dx.doi.org/10.1155/2018/9489163] [PMID: 29808169]

[100] Stanganelli I, Spagnolo F, Argenziano G, *et al.* The multidisciplinary management of cutaneous squamous cell carcinoma: A comprehensive review and clinical recommendations by a panel of experts. Cancers 2022; 14(2): 377. [http://dx.doi.org/10.3390/cancers14020377] [PMID: 35053539]

[101] Goldman G. The current status of curettage and electrodesiccation. Dermatol Clin 2002; 20(3): 569-578, ix. [http://dx.doi.org/10.1016/S0733-8635(02)00022-0] [PMID: 12170889]

[102] Bittner GC, Cerci FB, Kubo EM, Tolkachjov SN. Mohs micrographic surgery: A review of indications, technique, outcomes, and considerations. An Bras Dermatol 2021; 96(3): 263-77. [http://dx.doi.org/10.1016/j.abd.2020.10.004] [PMID: 33849752]

[103] Chanprapaph K, Vachiramon V, Rattanakaemakorn P. Epidermal growth factor receptor inhibitors: A review of cutaneous adverse events and management. Dermatol Res Pract 2014; 2014: 1-8. [http://dx.doi.org/10.1155/2014/734249] [PMID: 24723942]

[104] Gambini D, Passoni E, Nazzaro G, *et al.* Basal cell carcinoma and hedgehog pathway inhibitors: Focus on immune response. Front Med 2022; 9(June): 893063. [http://dx.doi.org/10.3389/fmed.2022.893063] [PMID: 35775005]